Pipeline
Advancing Central Nervous System Therapeutics
NurExone’s pipeline is built around its ExoTherapy Platform and led by ExoPTEN, a single nanodrug candidate being developed for several high-impact central nervous system injury indications.
ExoPTEN is being advanced first for acute spinal cord injury, with optic nerve damage as an additional CNS indication supported by preclinical research. In parallel, NurExone continues to explore additional applications for ExoPTEN and the broader platform, including collaborative research with the Technion in facial nerve injury and other potential nerve repair indications. Naïve exosomes are also being developed through Exo-Top as a separate commercial pathway that supports broader platform value.